Protagonist Therapeutics Inc (PTGX) CEO Sells $84,435.66 in Stock
Protagonist Therapeutics Inc (NASDAQ:PTGX) CEO Dinesh V. Ph D. Patel sold 10,909 shares of the business’s stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $7.74, for a total value of $84,435.66. Following the transaction, the chief executive officer now directly owns 367,396 shares of the company’s stock, valued at approximately $2,843,645.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
NASDAQ:PTGX opened at $7.10 on Monday. The stock has a market cap of $171.72 million, a PE ratio of -3.40 and a beta of 2.10. Protagonist Therapeutics Inc has a 1-year low of $5.49 and a 1-year high of $23.97.
Several brokerages have commented on PTGX. Zacks Investment Research raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 26th. ValuEngine downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Nomura started coverage on Protagonist Therapeutics in a report on Thursday, December 6th. They set a “buy” rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. Protagonist Therapeutics has an average rating of “Hold” and a consensus price target of $18.20.
TRADEMARK VIOLATION WARNING: This report was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://theolympiareport.com/2019/02/11/protagonist-therapeutics-inc-ptgx-ceo-sells-84435-66-in-stock.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
Featured Story: How do buyers and sellers choose a strike price?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.